The overuse of pesticides leads to contamination of water and food. Therefore, there is a need for tools and strategies to optimize pesticide application. Here we present SnapCard, a user-friendly and freely available decision support tool for farmers and agricultural consultants, available at snapcard.agric.wa.gov.au. SnapCard allows to predict, measure, and archive pesticide spray coverage quantified from water-sensitive spray cards. Variables include spray settings such as nozzle orifice size, sprayer speed, water carrier rate and adjuvant, and weather variables such as barometric pressure, relative humidity, temperature, and wind speed at ground level. We use separate regression models for four nozzles types. Our results showed that there are strong and positive correlations between water carrier rate and spray coverage for all four nozzle types. Moreover, sprayer speed is highly negatively correlated with obtained spray coverage. In addition, there is no consistent effect of either nozzle type or use of a particular adjuvant, across water carrier intervals. We conclude that varying combinations of spray settings and weather conditions caused marked ranges of spray coverages among the four nozzle types, thus highlighting the importance of selecting the right nozzle orifice size and type. We demonstrate that realistic scenarios of environmental conditions and spray settings can lead to predictions of very low spray coverage with at least one of the four nozzle types. We discuss how the novel and freely available smartphone app, SnapCard, can be used to optimize spray coverage, reduce spray drift, and minimize the risk of resistance development in target pest populations.

No abstract

No abstract

Objective Serotonergic psychedelics are re-emerging as potential novel treatments for several psychiatric disorders including major depressive disorder. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence and provide a consensus recommendation for the clinical use of psychedelic treatments for major depressive disorder. Methods A systematic review was conducted to identify contemporary clinical trials of serotonergic psychedelics for the treatment of major depressive disorder and cancer-related depression. Studies published between January 1990 and July 2021 were identified using combinations of search terms, inspection of bibliographies and review of other psychedelic reviews and consensus statements. The levels of evidence for efficacy were graded according to the Canadian Network for Mood and Anxiety Treatments criteria. Results Only psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. Two pilot studies showed preliminary positive effects of single-dose ayahuasca for treatment-resistant depression (Level 3 evidence). Small randomized controlled trials of psilocybin combined with psychotherapy showed superiority to waitlist controls and comparable efficacy and safety to an active comparator (escitalopram with supportive psychotherapy) in major depressive disorder, with additional randomized controlled trials showing efficacy specifically in cancer-related depression (Level 3 evidence). There was only one open-label trial of psilocybin in treatment-resistant unipolar depression (Level 4 evidence). Small sample sizes and functional unblinding were major limitations in all studies. Adverse events associated with psychedelics, including psychological (e.g., psychotomimetic effects) and physical (e.g., nausea, emesis and headaches) effects, were generally transient. Conclusions There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder. In Canada, as of 2022, psilocybin remains an experimental option that is only available through clinical trials or the special access program. As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances.

Intravenous ketamine is an effective treatment of bipolar depression. One of its most important side-effects is a transient altered state of consciousness commonly referred to as dissociation. These states can be anxiety-provoking, distressing and even treatment-limiting, warranting research into mitigation strategies. In this article, we present two cases that demonstrate the potential of adjunctive music to diminish the distress associated with ketamine-induced dissociation – though not necessarily its degree – in bipolar 1 disorder. Both patients suffering from severe depression underwent their first ketamine infusion without music and opted for music with subsequent infusions. They reported that music significantly improved the tolerance of their dissociative symptoms, thereby reducing distress and facilitating subsequent treatments. Both patients achieved remission from their highly treatment-resistant depressive episodes following six ketamine infusions. This is the first report of music’s benefits on ketamine for bipolar 1 depression, though there is precedence in the scientific literature on ‘psychedelics’ where the use of music in combination with medication-induced altered states has been studied. The principles regarding music selection that have resulted from this paradigm may be applicable to the use of ketamine in unipolar and bipolar depression. The optimal use of music with ketamine warrants further research.